Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)
31 5월 2022 - 11:25PM
Edgar (US Regulatory)
Filed by ECARX Holdings, Inc.
Pursuant to Rule 425 under the Securities Act of 1933,
as amended, and deemed filed
pursuant to Rule 14a-12
under the Securities Exchange Act of 1934, as amended
Subject Company: COVA Acquisition Corp.
Commission File
No.: 001-40012
ECARX LinkedIn Post – 05.26.22
Important Additional Information Regarding the Transaction Will
Be Filed With the SEC
In connection with the proposed transaction, ECARX Holdings, Inc. (“ECARX”)
will file a registration statement on Form F-4 with the U.S. Securities and Exchange Commission (the “SEC”) that will include
a prospectus with respect to ECARX’s securities to be issued in connection with the proposed transaction and a proxy statement with
respect to the shareholder meeting of COVA Acquisition Corp. (“COVA”) to vote on the proposed transaction. Shareholders of
COVA and other interested persons are encouraged to read, when available, the preliminary proxy statement/prospectus as well as other
documents to be filed with the SEC because these documents will contain important information about COVA and ECARX and the proposed transaction.
After the registration statement is declared effective, the definitive proxy statement/prospectus to be included in the registration statement
will be mailed to shareholders of COVA as of a record date to be established for voting on the proposed transaction. Once available, shareholders
of COVA will also be able to obtain a copy of the F-4, including the proxy statement/prospectus, and other documents filed with the SEC
without charge, by directing a request to: COVA Acquisition Corp., 530 Bush Street, Suite 703 San Francisco, California 94108. The preliminary
and definitive proxy statement/prospectus to be included in the registration statement, once available, can also be obtained, without
charge, at the SEC’s website (www.sec.gov).
Participants in the Solicitation
COVA and ECARX and their respective directors and executive officers
may be considered participants in the solicitation of proxies with respect to the potential transaction described in this communication
under the rules of the SEC. Information about the directors and executive officers of COVA and their ownership is set forth in COVA’s
filings with the SEC. Additional information regarding the persons who may, under the rules of the SEC, be deemed participants in the
solicitation of COVA’s shareholders in connection with the potential transaction will be set forth in the registration statement
containing the preliminary proxy statement/prospectus when it is filed with the SEC. These documents are available free of charge at the
SEC’s website at www.sec.gov or by directing a request to COVA Acquisition Corp., 530 Bush Street, Suite 703 San Francisco, California
94108.
No Offer or Solicitation
This communication is not a proxy statement or solicitation of a proxy,
consent or authorization with respect to any securities or in respect of the potential transaction and does not constitute an offer to
sell or a solicitation of an offer to buy any securities of COVA or ECARX, nor shall there be any sale of any such securities in any state
or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities
laws of such state or jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of the
Securities Act of 1933, as amended (the “Securities Act”).
Forward-Looking Statements
This communication contains forward-looking statements within the meaning
of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended, that are based on beliefs and
assumptions and on information currently available to COVA and ECARX.
All statements other than statements of historical fact contained in
this communication are forward-looking statements. In some cases, you can identify forward-looking statements by the following words:
“may,” “will,” “could,” “would,” “should,” “expect,” “intend,”
“plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,”
“potential,” “continue,” “ongoing,” “target,” “seek” or the negative or plural
of these words, or other similar expressions that are predictions or indicate future events or prospects, although not all forward-looking
statements contain these words. These statements are based upon estimates and forecasts and reflect the views, assumptions, expectations,
and opinions of COVA and ECARX, which involve risks, uncertainties and other factors that may cause actual results, levels of activity,
performance or achievements to be materially different from those expressed or implied by these forward-looking statements. Any such estimates,
assumptions, expectations, forecasts, views or opinions, whether or not identified in this communication, should be regarded as preliminary
and for illustrative purposes only and should not be relied upon as being necessarily indicative of future results. Although each of COVA
and ECARX believes that it has a reasonable basis for each forward-looking statement contained in this communication, each of COVA and
ECARX caution you that these statements are based on a combination of facts and factors currently known and projections of the future,
which are inherently uncertain. In addition, there will be risks and uncertainties described in the proxy statement/prospectus on Form
F-4 relating to the proposed transaction, which is expected to be filed by ECARX with the SEC and other documents filed by COVA or ECARX
from time to time with the SEC. These filings may identify and address other important risks and uncertainties that could cause actual
events and results to differ materially from those expressed or implied in the forward-looking statements. Neither COVA nor ECARX can
assure you that the forward-looking statements in this communication will prove to be accurate. These forward-looking statements are subject
to a number of risks and uncertainties, including the ability to complete the business combination due to the failure to obtain approval
from COVA shareholders or satisfy other closing conditions in the merger agreement, the occurrence of any event that could give rise to
the termination of the merger agreement, the ability to recognize the anticipated benefits of the business combination, the amount of
redemption requests made by COVA public shareholders, costs related to the transaction, the impact of the global COVID-19 pandemic, the
risk that the transaction disrupts current plans and operations as a result of the announcement and consummation of the transaction, the
outcome of any potential litigation, government or regulatory proceedings and other risks and uncertainties, including those to be included
under the heading “Risk Factors” in the registration statement on Form F-4 to be filed by ECARX with the SEC and those included
under the heading “Risk Factors” in the final prospectus of COVA dated February 4, 2021 and in its subsequent filings with
the SEC. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation
or warranty by COVA or ECARX, their respective directors, officers or employees or any other person that COVA or ECARX will achieve their
objectives and plans in any specified time frame, or at all. The forward-looking statements in this communication represent the views
of COVA and ECARX as of the date of this communication. Subsequent events and developments may cause those views to change. However, while
COVA and ECARX may update these forward-looking statements in the future, COVA and ECARX specifically disclaim any obligation to do so,
except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing the
views of COVA and ECARX as of any date subsequent to the date of this communication. Accordingly, undue reliance should not be placed
upon the forward-looking statements.
COVA Acquisition (NASDAQ:COVA)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
COVA Acquisition (NASDAQ:COVA)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024